The FDA Wants Food Companies to Start Phasing Out All Artificial Dyes
Several synthetic food dyes have been targeted for removal from the food supply. Two rarely used dyes—Citrus Red No. 2 and Orange B—will no longer be allowed to be used. Red No. 3, which has been flagged as a potential carcinogen, will be phased out sooner than previously agreed. Six other food dyes have been highlighted for a voluntary phase-out—but manufacturer lobbying groups are pushing back.
Some synthetic food dyes have been linked in studies to hyperactivity in people with ADHD, and cancer and tumor growth in lab rats.
Naturally derived dyes like vegetable juices and flower extracts are being suggested for potential use in lieu of artificial food dyes.The Food and Drug Administration (FDA) announced an attempt to phase out artificial dyes from the food supply. The FDA will revoke authorization for two rarely used food colorings, ask food manufacturers to phase out six other popular synthetic dyes, and move up the timeline for removing FD&C Red No. 3. But the announcement may do little to get artificial dyes out of foods, as most of the synthetic food dyes used today would only be subject to a voluntary removal.
Related: Food Additives to Watch Out For—and Where You'll Find Them
Artificial food dyes are petroleum-based products that add or enhance color in ultra-processed foods. They're basically the reason why candy is, well, candy-colored, in bright rainbow shades. But synthetic food dyes aren't just relegated to sweets or obviously dyed foods. They can be used to make subtle color shifts in everything from beef jerky to barbecue sauces to salad dressings to give them a more palatable hue.
Artificial food dyes have been a subject of concern. Several studies have linked artificial food dyes to issues like hyperactivity in people with ADHD, and some animal studies found potential links to cancer and some synthetic dyes, according to the Center for Science in the Public Interest (CSPI). Red No. 3 was banned from cosmetics in 1990 as it was shown to cause cancer in lab rats—but that was decades before the phase-out from foods began earlier this year.
Several different tactics are being used in this announcement, and some have more teeth than others.
The two food colorings that will have their authorization revoked are Citrus Red No. 2 and Orange B—and revoking authorization ensures these dyes are off the market. However, Citrus Red No. 2 is currently only used for dyeing the skins of oranges, and it is used in such small amounts that the health risk is minimal. Orange B was once used to color hot dogs and sausages, but it hasn't been used in decades, after the FDA proposed (but never finalized) a ban in 1978, according to CSPI. "The only real regulatory moves here are to move to ban two rarely used dyes, Citrus Red 2 and Orange B, 'within the coming months,'" says Peter G. Lurie, president of the CSPI, in a statement.
There are six dyes the FDA would like to phase out with a voluntary "understanding" with food manufacturers:
FD&C Green No. 3
FD&C Red No. 40
FD&C Yellow No. 5
FD&C Yellow No. 6
FD&C Blue No. 1
FD&C Blue No. 2
But because it's an "understanding," food manufacturers can ignore it—and some manufacturers have already come out with statements defending the safety of these food dyes. This suggests that some food companies may ignore the FDA's recommendations. "The ingredients used in America's food supply have been rigorously studied following an objective science and risk-based evaluation process and have been demonstrated to be safe," says Melissa Hockstad, president and CEO of the Consumer Brands Association, a lobbying organization that represents U.S. packaged food manufacturers, in a statement.
FD&C Red No. 3 was scheduled to be removed from foods and oral drugs by 2028, but the FDA announced that they plan to shorten the deadline for companies to remove the dye from their foods—with no specific timeline announced.
Related: 8 Red Flags to Look Out for on Food Labels, According to Nutrition Experts
The FDA suggests replacing artificial food dyes with natural options—which could include extracts and juices from vegetables, fruits, flowers, and minerals. The FDA plans to fast-track research into alternative food dyes such as calcium phosphate, Galdieria extract blue, gardenia blue, and butterfly pea flower extract.
In general, new products to the market may be the first to see these changes, as food companies may add the natural dyes to them before they start changing older food formulations. But because food manufacturers aren't legally required to remove the commonly used artificial food colorants from their foods, the government may need to revoke authorization down the line to actually get them out of the food supply.
In general, highly processed foods, such as snack foods, candy, baked goods, and soft drinks, tend to feature high quantities of artificial dyes. (Those bright reds and neon greens in everything from Flamin' Hot Cheetos to M&Ms come from synthetic food dyes.)
To get a sense of what foods may have high levels of these food dyes, you can use the Environmental Working Group's Food Scores Tool, where you can search by product or ingredient to look for specific food dyes in the foods you eat. Products that contain synthetic dyes need to disclose them on their labels, so you can also review the foods in your pantry and fridge to see if they contain the six food dyes that the government is hoping manufacturers will remove from foods.
Read the original article on Real Simple
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
The Webb telescope found something exceedingly rare around a dying star
The Ring Nebula is a well-known space icon shaped like a doughnut about 2,500 light-years away in the constellation Lyra. But astronomers think it's been holding a secret that only the penetrating gaze of the James Webb Space Telescope, a joint project of NASA and the European and Canadian space agencies, could reveal. Using Webb's infrared-sensing MIRI instrument, scientists got a clear sightline to the small but scorching star at its center. The shriveled core — a white dwarf — is all that remains of the star on its deathbed, having molted its outermost layers. When researchers zoomed in, they got a surprise. Surrounding the withering star was a disk of dust, much like the kind found around new stars that are in their prime planet-birthing years. It was kind of like seeing a pregnant octogenarian in a nursing home. This is just the second time scientists have observed such a disk around a star at the end of its life. And though they can't actually see baby planets in their nebula images, they are now wondering if these space environments could trigger a second generation of planets, long after the original brood of worlds formed around the star. The discovery, published in The Astrophysical Journal, is "raising questions about their nature, formation, longevity, and potentially a second phase of planet formation," the authors wrote. SEE ALSO: Spectacular Webb telescope image shows a stellar death like never before The James Webb Space Telescope provides a clear view of the central white dwarf creating the Ring Nebula in the left image. Credit: NASA / ESA / CSA / Raghvendra Sahai et al. Unlike giant stars that explode into a supernova and collapse into a black hole when their time is up, a medium star gradually runs out of nuclear fuel and suffers a more prolonged death. These stars, like our midsize sun in perhaps 5 billion years, decline into so-called planetary nebulas, a confusing misnomer for the phenomenon because they have more to do with aging stars than planets. Scientists have discovered a few thousand planetary nebulas in the Milky Way. Those include the Ring Nebula, aka NGC 6720 and Messier 57. With Webb, the researchers could see a compact dust cloud around the central white dwarf creating it. "These are first seen as the gas-and-dust-rich planet-forming disks in young stellar objects, and are an integral part of the star formation process itself," the authors wrote. "Remarkably, dusty disks or disk-like structures manifest themselves again as these stars reach the ends of their lives." Such a rare sighting is believed to have happened once before, when astronomers got a look at the Southern Ring Nebula with Webb, at wavelengths far beyond what people can see with their eyes. In the first images, astronomers were amazed to spot the true source of the nebula, said Karl Gordon, an astronomer at the Space Telescope Science Institute in Baltimore. "We knew this was a binary star (beforehand), but we effectively didn't really see much of the actual star that produced the nebula," he said during a 2022 news conference. "But now in MIRI, this star glows red because it has dust around it." The James Webb Space Telescope spots a dusty disk around the central white dwarf powering the Ring Nebula. Credit: NASA GSFC / CIL / Adriana Manrique Gutierrez illustration The dust cloud around the Ring Nebula is composed of tiny grains of amorphous silicate, a glass-like substance, according to the new paper. These particles are miniscule, perhaps less than one-thousandth the thickness of a human hair. The cloud itself stretches thousands of times wider than the distance between the Earth and the sun. The researchers noticed something else intriguing at the center of the nebula. The white dwarf's brightness keeps changing. That might be a clue that another star is lurking in the shadows nearby, perhaps a small-but-feisty red dwarf star. While scientists haven't directly spotted the buddy yet, they can infer it's there from patterns in the nebula. The study could help confirm earlier findings that suggested the star had two companions — one far in the outskirts of the system and another nearby. A close star could explain the strange arcs and rings seen around the nebula.
Yahoo
2 hours ago
- Yahoo
These Popular Eggs Are Being Recalled Over Salmonella Risk
If you've been living for your morning sunny-side eggs…well, brace yourself. The August Egg Company—the parent behind Sunnyside, Clover, Raley's, and a few other brands—is recalling a whopping 1.7 million dozen eggs due to a potential salmonella outbreak. Yep, it's serious.. The U.S. Food and Drug Administration (FDA) and Centers for Disease Control and Prevention have flagged the August Company's 'brown cage-free and brown certified organic egg' for possible contamination, meaning you might want to double-check that carton in your fridge before cracking it open. If you didn't know, Salmonella is that sneaky bacteria behind food poisoning and can cause anything from mild stomach upset to serious illness. These eggs were shipped to Walmart stores and other grocers in nine states: California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana, and Illinois. They have a best-by date from March 4 to June 19 and food codes P-6562 or CA5330. Not sure if your eggs are on the list? The FDA has a full rundown of all the recalled brands you can check out. And if the cartons in your fridge match any of the food codes or best-by-dates, toss them out immediately. While it's somewhat okay to eat an egg past its expiration date, this isn't the case. The FDA has already connected a current salmonella outbreak to the eggs. As of now, a total of 79 cases have been reported in seven states, while 21 people have been hospitalized. We get it: eggs are pricey, and tossing them feels like a waste. But don't risk it. Plus, most places will give you a full refund. And if your eggs touched any surfaces, wipe those down like your life depends on it. If after eating you feel dizzy, nauseous, or get a fever—don't play it cool. Call your doctor. This is serious business. Trust me, as a four-time survivor of food poisoning, you don't want to take any chances. You Might Also Like Insanely Easy Weeknight Dinners To Try This Week 29 Insanely Delicious Vodka Cocktails
Yahoo
4 hours ago
- Yahoo
ADHD drugs back in the spotlight after study debunks rising prevalence
An increasing number of patients are seeking support for attention-deficit/hyperactivity disorder (ADHD), with pharmacological-based treatments an important part of medical care for the neurodevelopmental condition. A study published this week in the Journal of Affective Disorders has found that greater awareness and acceptance around the disorder has led to more people seeking help. The research, led by a team at King's College, London, debunks claims that the disorder is 'naturally' on the rise. The data comes as a national taskforce in England investigates what this rising demand for support means for the NHS. Figures published in May 2025 by NHS England estimated there were nearly 2.5 million people in England with ADHD. This includes more than 550,000 currently waiting for an assessment. Every month 20,000 more people are referred for support, a rise of 13% compared to last year. Pharmaceutical Technology looks at some of the current options in the UK and casts an eye ahead to what the future drug landscape might contain. The first choice for patients with ADHD is methylphenidate, which belongs to a class of drugs called central nervous system (CNS) stimulants. The drug, which works by blocking the reuptake of norepinephrine and dopamine, increases activity in the brain, including regions associated with attention and behaviour. It is known under the brand names Ritalin, manufactured by Novartis, and Johnson and Johnson's Concerta. There is also Equasym and Xenidate, among others. Lisdexamfetamine dimesylate is also used to treat patients with ADHD. Like methylphenidate, lisdexamfetamine is a CNS stimulant and acts as a norepinephrine and dopamine reuptake inhibitor (NDRI). This drug is known under the brand name, among others, as Elvanse and Vyvanse, both manufactured by Takeda. While stimulants are fast acting, with side effects felt soon after administration, non-stimulant drugs take longer, yet can offer an alternative if drugs like methylphenidate and lisdexamfetamine dimesylate do not work. While improving, access to pharmacological-based treatments is still impaired amid an ongoing global shortage that began in September 2023. Methylphenidate and lisdexamfetamine were primarily affected – the shortage arising due to a combination of manufacturing issues and increased global demand. A separate study published in The American Journal of Managed Care in March suggested that overdiagnosis of ADHD is fuelling the shortage of stimulation medications. One of the most advanced candidate drugs, and one with notable buzz surrounding it, is Axsome's Sunosi (solriamfetol). Sunosi, which is also an NDRI but not a conventional stimulant, met its primary endpoint in a Phase III trial (NCT05972044) earlier this year. The medication led to a 45% drop in ADHD symptoms. As measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS), 150mg Sunosi dosed achieved average reductions from baseline of 17.7 points, compared to 14.3 points for placebo. Sunosi is already approved in the UK to treat excessive daytime sleepiness (EDS) in adults with narcolepsy, with or without cataplexy. Certain patients with obstructive sleep apnoea (OSA) are also eligible to take the medication. In 2022, Axsome paid $53m up front to acquire Sunosi from Jazz Pharmaceuticals. A drug with a recent approval extension in the US, though not the UK, was Supernus Pharmaceuticals' Qelbree (viloxazine extended-release capsules). The mechanism of action of Qelbree, though unclear, is thought to be through inhibiting the reuptake of norepinephrine. Originally approved for children in 2021, the FDA updated the drug's label in January this year to include adults. ADHD treatments were in the political crosshairs in the US recently. The disorder, along with autism, was singled out by the Trump administration for an 'over-utilisation of medication'. Pharmaceutical intervention remains a helpful part of managing the disorder, though it is part of a combination of treatments that also include coaching and lifestyle changes. "ADHD drugs back in the spotlight after study debunks rising prevalence" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data